Read Research Alzheimer's More' title='Share this by email.' class='social email'>           

Anavex announces positive dose-response data for ANAVEX 2-73 in Alzheimer's disease patients

Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other… Read & Research Alzheimer’s More

Leave a Reply